| pubmed-article:18782042 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18782042 | lifeskim:mentions | umls-concept:C0033684 | lld:lifeskim |
| pubmed-article:18782042 | lifeskim:mentions | umls-concept:C0334227 | lld:lifeskim |
| pubmed-article:18782042 | lifeskim:mentions | umls-concept:C0242640 | lld:lifeskim |
| pubmed-article:18782042 | lifeskim:mentions | umls-concept:C1956072 | lld:lifeskim |
| pubmed-article:18782042 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:18782042 | lifeskim:mentions | umls-concept:C0220781 | lld:lifeskim |
| pubmed-article:18782042 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
| pubmed-article:18782042 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:18782042 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:18782042 | pubmed:dateCreated | 2008-9-10 | lld:pubmed |
| pubmed-article:18782042 | pubmed:abstractText | A series of N10-substituted-2-methyl acridone derivatives are synthesized and are examined for its ability to reverse P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in breast cancer cell lines MCF-7 and MCF-7/Adr. The structural requirement of in-vitro anti-cancer and reversal of drug resistance are studied. The results showed that compound 16 with four carbon spacer exhibited promising in-vitro anti-cancer and reversal of drug resistance in comparison to the other analogues. | lld:pubmed |
| pubmed-article:18782042 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18782042 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18782042 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18782042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18782042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18782042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18782042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18782042 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18782042 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:18782042 | pubmed:issn | 1573-4064 | lld:pubmed |
| pubmed-article:18782042 | pubmed:author | pubmed-author:SrinivasuluNN | lld:pubmed |
| pubmed-article:18782042 | pubmed:author | pubmed-author:MayurY CYC | lld:pubmed |
| pubmed-article:18782042 | pubmed:author | pubmed-author:AhmadOsmanO | lld:pubmed |
| pubmed-article:18782042 | pubmed:author | pubmed-author:PrasadV V S... | lld:pubmed |
| pubmed-article:18782042 | pubmed:author | pubmed-author:PurohitM NMN | lld:pubmed |
| pubmed-article:18782042 | pubmed:author | pubmed-author:KumarS M... | lld:pubmed |
| pubmed-article:18782042 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18782042 | pubmed:volume | 4 | lld:pubmed |
| pubmed-article:18782042 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18782042 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18782042 | pubmed:pagination | 457-65 | lld:pubmed |
| pubmed-article:18782042 | pubmed:meshHeading | pubmed-meshheading:18782042... | lld:pubmed |
| pubmed-article:18782042 | pubmed:meshHeading | pubmed-meshheading:18782042... | lld:pubmed |
| pubmed-article:18782042 | pubmed:meshHeading | pubmed-meshheading:18782042... | lld:pubmed |
| pubmed-article:18782042 | pubmed:meshHeading | pubmed-meshheading:18782042... | lld:pubmed |
| pubmed-article:18782042 | pubmed:meshHeading | pubmed-meshheading:18782042... | lld:pubmed |
| pubmed-article:18782042 | pubmed:meshHeading | pubmed-meshheading:18782042... | lld:pubmed |
| pubmed-article:18782042 | pubmed:meshHeading | pubmed-meshheading:18782042... | lld:pubmed |
| pubmed-article:18782042 | pubmed:meshHeading | pubmed-meshheading:18782042... | lld:pubmed |
| pubmed-article:18782042 | pubmed:meshHeading | pubmed-meshheading:18782042... | lld:pubmed |
| pubmed-article:18782042 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18782042 | pubmed:articleTitle | Synthesis of 2-methyl N10-substituted acridones as selective inhibitors of multidrug resistance (MDR) associated protein in cancer cells. | lld:pubmed |
| pubmed-article:18782042 | pubmed:affiliation | Department of Medical Oncology, Cancer Center Amsterdam, VU Medical Center, Amsterdam, The Netherlands. mayuryc@rediffmail.com | lld:pubmed |
| pubmed-article:18782042 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18782042 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
